JP2011515478A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515478A5 JP2011515478A5 JP2011501946A JP2011501946A JP2011515478A5 JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5 JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- antibody
- cdr
- ser
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3919708P | 2008-03-25 | 2008-03-25 | |
| US61/039,197 | 2008-03-25 | ||
| PCT/US2009/037953 WO2009142810A2 (en) | 2008-03-25 | 2009-03-23 | Methods for treating or preventing colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515478A JP2011515478A (ja) | 2011-05-19 |
| JP2011515478A5 true JP2011515478A5 (OSRAM) | 2013-03-14 |
Family
ID=41340744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501946A Pending JP2011515478A (ja) | 2008-03-25 | 2009-03-23 | 結腸直腸がんを処置または予防するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110104256A1 (OSRAM) |
| EP (1) | EP2259797A2 (OSRAM) |
| JP (1) | JP2011515478A (OSRAM) |
| CA (1) | CA2718918A1 (OSRAM) |
| CL (1) | CL2009000721A1 (OSRAM) |
| MX (1) | MX2010010480A (OSRAM) |
| TW (1) | TW200944233A (OSRAM) |
| WO (1) | WO2009142810A2 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| WO2010093789A2 (en) | 2009-02-12 | 2010-08-19 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US8580764B2 (en) * | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| TW201221126A (en) | 2010-09-01 | 2012-06-01 | Arqule Inc | Methods for treatment of non-small cell lung cancer |
| NL2010276C2 (en) * | 2013-02-08 | 2014-08-11 | Stichting Vu Vumc | Biomarkers. |
| EP2841947B1 (en) * | 2012-04-26 | 2019-10-09 | Stichting VUmc | Biomarkers |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| JP6210640B2 (ja) * | 2014-06-19 | 2017-10-11 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| WO2016054055A1 (en) * | 2014-09-29 | 2016-04-07 | Board Of Regent, The University Of Texas System | Prediction of response to parp inhibitors and combinational therapy targeting c-met and parp1 |
| JP2018517892A (ja) | 2015-04-10 | 2018-07-05 | アプライド プロテオミクス，インク． | 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| PL3337467T3 (pl) | 2015-08-20 | 2021-06-14 | Ipsen Biopharm Ltd. | Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu |
| PL3337478T5 (pl) | 2015-08-21 | 2026-05-04 | Ipsen Biopharm Ltd. | Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami |
| WO2017136671A1 (en) * | 2016-02-04 | 2017-08-10 | Chattterjee Bandana | Combination therapy for castration-resistant prostate cancer |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| JP2017210493A (ja) * | 2017-09-08 | 2017-11-30 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| WO2020100969A1 (ja) * | 2018-11-14 | 2020-05-22 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| JP2021036003A (ja) * | 2020-12-05 | 2021-03-04 | 大原薬品工業株式会社 | ホリナートカルシウム含有錠 |
| MX2024000965A (es) * | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8535501A1 (es) * | 2001-01-05 | 2003-07-28 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| NZ536475A (en) * | 2002-05-24 | 2008-06-30 | Schering Corp | Neutralizing human anti-igfr antibody |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| DK1656391T3 (da) * | 2003-08-13 | 2011-01-03 | Pfizer Prod Inc | Modificerede humane IGF-1R antistoffer |
| PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
| JP2008513435A (ja) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物 |
| US20060233810A1 (en) * | 2005-04-15 | 2006-10-19 | Yaolin Wang | Methods and compositions for treating or preventing cancer |
| AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
| US20080299113A1 (en) * | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US20080112888A1 (en) * | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
| US20100143340A1 (en) * | 2006-12-13 | 2010-06-10 | Schering Corporation | Methods and compositions for treating cancer |
| CA2722992A1 (en) * | 2008-05-05 | 2009-11-12 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
-
2009
- 2009-03-23 EP EP09751040A patent/EP2259797A2/en not_active Withdrawn
- 2009-03-23 WO PCT/US2009/037953 patent/WO2009142810A2/en not_active Ceased
- 2009-03-23 MX MX2010010480A patent/MX2010010480A/es not_active Application Discontinuation
- 2009-03-23 US US12/934,458 patent/US20110104256A1/en not_active Abandoned
- 2009-03-23 CA CA2718918A patent/CA2718918A1/en not_active Abandoned
- 2009-03-23 JP JP2011501946A patent/JP2011515478A/ja active Pending
- 2009-03-24 CL CL2009000721A patent/CL2009000721A1/es unknown
- 2009-03-24 TW TW098109578A patent/TW200944233A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519868A5 (OSRAM) | ||
| JP2019503674A5 (OSRAM) | ||
| WO2008076278A4 (en) | Methods of cancer treatment with igf1r inhibitors | |
| RU2010120674A (ru) | Полностью человеческие анти-vegf-антитела и способы их применения | |
| JP2012247438A5 (OSRAM) | ||
| RU2018123481A (ru) | Анти-lag3 антитела и антигенсвязывающие фрагменты | |
| WO2010124009A2 (en) | Fully human anti-vegf antibodies and methods of using | |
| JP2014516964A5 (OSRAM) | ||
| AU2016355569B2 (en) | CTLA4 binders | |
| US10544222B2 (en) | PD1/CTLA4 binders | |
| US10323090B2 (en) | PD1 and/or LAG3 binders | |
| WO2019199621A4 (en) | Bi-functional molecules to degrade circulating proteins | |
| IL319363A (en) | Cervalon ligands and bifunctional compounds containing them | |
| JP2022549169A5 (OSRAM) | ||
| WO2009137378A2 (en) | Sequential administration of chemotherapeutic agents for treatment of cancer | |
| JP2011515478A (ja) | 結腸直腸がんを処置または予防するための方法 | |
| JP2005527222A5 (ja) | 中和ヒト抗ｉｇｆｒ抗体 | |
| JP2014516964A (ja) | 治療用抗ｉｇｆ１ｒ合剤 | |
| KR20170065466A (ko) | 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체 | |
| TWI913270B (zh) | 用於癌症治療之結合分子 | |
| JP2017538673A5 (OSRAM) | ||
| IL323835A (en) | Bifunctional small molecules to target the selective degradation of circulating proteins | |
| JP2025509736A5 (OSRAM) | ||
| US9346846B1 (en) | Anti-cancer compounds and methods for treating cancer | |
| AU2018375719A1 (en) | Compositions and methods for cancer therapy |